Website
News25/Ratings12
News · 26 weeks32-70%
2025-10-262026-04-19
Mix1490d
- SEC Filings5(36%)
- Insider4(29%)
- Earnings3(21%)
- Offering1(7%)
- Other1(7%)
Latest news
25 items- SECSEC Form DEFA14A filed by Pulmonx CorporationDEFA14A - Pulmonx Corp (0001127537) (Filer)
- SECSEC Form DEF 14A filed by Pulmonx CorporationDEF 14A - Pulmonx Corp (0001127537) (Filer)
- PRPulmonx to Report First Quarter 2026 Financial Results on April 29, 2026REDWOOD CITY, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the first quarter of 2026 after the close of trading on Wednesday, April 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatments for chroni
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pulmonx CorporationSCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)
- SECSEC Form S-8 filed by Pulmonx CorporationS-8 - Pulmonx Corp (0001127537) (Filer)
- SECSEC Form 10-K filed by Pulmonx Corporation10-K - Pulmonx Corp (0001127537) (Filer)
- INSIDERChief Science &Techn. Officer Radhakrishnan Srikanth sold $14,991 worth of shares (10,483 units at $1.43) and was granted 175,000 shares, increasing direct ownership by 91% to 345,736 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERPresident and CEO French Glendon E. Iii sold $96,973 worth of shares (67,813 units at $1.43), decreasing direct ownership by 5% to 1,409,511 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERCHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $11,057 worth of shares (7,732 units at $1.43) and was granted 100,000 shares, increasing direct ownership by 25% to 465,734 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERGENERAL COUNSEL Lehman David Aaron sold $17,499 worth of shares (12,237 units at $1.43) and was granted 150,000 shares, increasing direct ownership by 54% to 390,755 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- SECPulmonx Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Pulmonx Corp (0001127537) (Filer)
- PRPulmonx Reports Fourth Quarter and Full Year 2025 Financial ResultsREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basisAchieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basisRealized gross margin of 78% in the fourth quarter of 2025 and 7
- PRPulmonx Announces Closing of up to $60 Million Credit FacilityREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced the closing of a five-year credit facility for up to $60 million with Perceptive Advisors. The credit facility consists of an initial $40 million term loan drawn at closing to refinance the Company's existing debt, and an option to draw an additional $20 million in unfunded capital through the end of 2027, subject to the achievement of certain revenue milestones. The new facility is interest only until maturity in 2031, and bears interest at a rate equal to one-month Term SOFR (subject to
- PRPulmonx to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026REDWOOD CITY, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2025 after the close of trading on Wednesday, March 4, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the "Investors" section of the Pulmonx website at https://investors.pulmonx.com/. About Pulmonx CorporationPulmonx Corporation (NASDAQ:LUNG) is a global leader in minimally invasive treatmen
- INSIDERNew insider Radhakrishnan Srikanth claimed ownership of 181,219 shares (SEC Form 3)3 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERDirector Florin Daniel P sold $46,409 worth of shares (23,321 units at $1.99), decreasing direct ownership by 20% to 93,910 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERPresident and CEO French Glendon E. Iii sold $13,824 worth of shares (8,805 units at $1.57) and was granted 1,200,000 shares, increasing direct ownership by 416% to 1,477,324 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERCHIEF COMMERCIAL OFFICER Rose Geoffrey Beran sold $9,926 worth of shares (6,322 units at $1.57), decreasing direct ownership by 2% to 373,466 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERCOO and CFO Sung Derrick was granted 1,200,000 shares, increasing direct ownership by 887% to 1,335,319 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- INSIDERGENERAL COUNSEL Lehman David Aaron sold $16,136 worth of shares (10,278 units at $1.57), decreasing direct ownership by 4% to 252,992 units (SEC Form 4)4 - Pulmonx Corp (0001127537) (Issuer)
- PRPulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)REDWOOD CITY, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) (the "Company" or "Pulmonx"), a global leader in minimally invasive treatments for lung disease, today announced that on December 1, 2025 (the "Grant Date"), Pulmonx granted equity awards under its 2025 Inducement Plan (the "Inducement Plan") for an aggregate of 1,625,000 shares of Pulmonx's common stock to two individuals hired by Pulmonx in the fourth quarter of 2025, including Pulmonx's Chief Financial Officer and Chief Operating Officer, Derrick Sung. The awards were approved by the Compensation Committee of the Company's Board of Directors and were granted as an inducement material to the new emp
- SECSEC Form EFFECT filed by Pulmonx CorporationEFFECT - Pulmonx Corp (0001127537) (Filer)
- SECAmendment: SEC Form S-3/A filed by Pulmonx CorporationS-3/A - Pulmonx Corp (0001127537) (Filer)
- SECSEC Form S-8 filed by Pulmonx CorporationS-8 - Pulmonx Corp (0001127537) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Pulmonx CorporationSCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)